Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors

Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis